SG10201912134TA - Methods and composition for the prediction of the activity of enzastaurin - Google Patents
Methods and composition for the prediction of the activity of enzastaurinInfo
- Publication number
- SG10201912134TA SG10201912134TA SG10201912134TA SG10201912134TA SG10201912134TA SG 10201912134T A SG10201912134T A SG 10201912134TA SG 10201912134T A SG10201912134T A SG 10201912134TA SG 10201912134T A SG10201912134T A SG 10201912134TA SG 10201912134T A SG10201912134T A SG 10201912134TA
- Authority
- SG
- Singapore
- Prior art keywords
- enzastaurin
- prediction
- activity
- composition
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382734P | 2016-09-01 | 2016-09-01 | |
| US201662414601P | 2016-10-28 | 2016-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912134TA true SG10201912134TA (en) | 2020-02-27 |
Family
ID=59923555
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912134TA SG10201912134TA (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
| SG11201901762WA SG11201901762WA (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901762WA SG11201901762WA (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11421280B2 (en) |
| EP (1) | EP3507384B1 (en) |
| JP (3) | JP7197915B2 (en) |
| KR (1) | KR20190046935A (en) |
| CN (1) | CN109952383B (en) |
| AU (1) | AU2017318669B2 (en) |
| BR (1) | BR112019003951A2 (en) |
| CA (1) | CA3035386A1 (en) |
| JO (1) | JOP20190025A1 (en) |
| MX (1) | MX2019002377A (en) |
| PH (1) | PH12019500422A1 (en) |
| RU (1) | RU2019109011A (en) |
| SG (2) | SG10201912134TA (en) |
| TW (2) | TWI771317B (en) |
| WO (1) | WO2018045240A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190025A1 (en) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | Methods and composition for the prediction of the activity of enzastaurin |
| CN110496223B (en) * | 2018-05-17 | 2021-09-10 | 复旦大学附属肿瘤医院 | Pharmaceutical composition for treating non-Hodgkin's lymphoma |
| WO2020055698A1 (en) * | 2018-09-12 | 2020-03-19 | Denovo Biopharma Llc | Combination of enzastaurin and inhibitors of btk and uses thereof |
| CN111549033B (en) * | 2020-06-11 | 2021-02-12 | 南京市江宁医院 | Lentiviral-infected human epidermal keratinocyte strain and construction method and application thereof |
| US11227690B1 (en) * | 2020-09-14 | 2022-01-18 | Opendna Ltd. | Machine learning prediction of therapy response |
| WO2023001178A1 (en) * | 2021-07-23 | 2023-01-26 | 高雄医学大学 | Clinical therapeutic drug prediction and recommendation system and method for evaluating efficacy of second-generation hormone drug in treatment of prostate cancer |
| WO2023097197A2 (en) * | 2021-11-23 | 2023-06-01 | Denovo Biopharma Llc | Compositions and methods for assessing the efficacy of polynucleotide delivery and cancer therapy |
| US20230185457A1 (en) * | 2021-12-13 | 2023-06-15 | Google Llc | Optimizing Data Placement Based on Data Temperature and Lifetime Prediction |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2179650C (en) | 1993-12-23 | 2007-10-30 | William Francis Heath, Jr. | Bisindolemaleimides and their use as protein kinase c inhibitors |
| JP2004512029A (en) * | 2000-08-16 | 2004-04-22 | カイロン コーポレイション | Human genes and gene expression products |
| US20040072217A1 (en) | 2002-06-17 | 2004-04-15 | Affymetrix, Inc. | Methods of analysis of linkage disequilibrium |
| CA2393720C (en) | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| WO2007145992A2 (en) | 2006-06-05 | 2007-12-21 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| US20140031242A1 (en) | 2011-01-31 | 2014-01-30 | Denovobiomarkers Inc. | Method for discovering pharmacogenomic biomarkers |
| RU2013158861A (en) | 2011-06-08 | 2015-07-20 | Деново Байофарма (Ханчжоу) Лтд.Ко. | METHODS AND COMPOSITIONS FOR PREDICTING THE ACTIVITY OF A RETINOID X-RECEPTOR MODULATOR |
| JOP20190025A1 (en) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | Methods and composition for the prediction of the activity of enzastaurin |
-
2017
- 2017-06-16 JO JOP/2019/0025A patent/JOP20190025A1/en unknown
- 2017-08-31 SG SG10201912134TA patent/SG10201912134TA/en unknown
- 2017-08-31 JP JP2019512609A patent/JP7197915B2/en active Active
- 2017-08-31 US US16/327,788 patent/US11421280B2/en active Active
- 2017-08-31 SG SG11201901762WA patent/SG11201901762WA/en unknown
- 2017-08-31 TW TW106129838A patent/TWI771317B/en active
- 2017-08-31 TW TW111122709A patent/TW202313973A/en unknown
- 2017-08-31 CA CA3035386A patent/CA3035386A1/en active Pending
- 2017-08-31 RU RU2019109011A patent/RU2019109011A/en unknown
- 2017-08-31 EP EP17771623.0A patent/EP3507384B1/en active Active
- 2017-08-31 CN CN201780066737.5A patent/CN109952383B/en active Active
- 2017-08-31 KR KR1020197009407A patent/KR20190046935A/en not_active Application Discontinuation
- 2017-08-31 WO PCT/US2017/049747 patent/WO2018045240A1/en active Application Filing
- 2017-08-31 BR BR112019003951A patent/BR112019003951A2/en not_active IP Right Cessation
- 2017-08-31 AU AU2017318669A patent/AU2017318669B2/en active Active
- 2017-08-31 MX MX2019002377A patent/MX2019002377A/en unknown
-
2019
- 2019-02-27 PH PH12019500422A patent/PH12019500422A1/en unknown
-
2020
- 2020-08-26 JP JP2020142358A patent/JP2020188816A/en active Pending
-
2022
- 2022-08-18 US US17/820,772 patent/US20230074781A1/en active Pending
- 2022-09-16 JP JP2022148064A patent/JP2022173308A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN109952383A (en) | 2019-06-28 |
| RU2019109011A (en) | 2020-10-05 |
| EP3507384B1 (en) | 2023-08-30 |
| AU2017318669A1 (en) | 2019-03-07 |
| BR112019003951A2 (en) | 2019-06-25 |
| CA3035386A1 (en) | 2018-03-08 |
| AU2017318669B2 (en) | 2023-04-20 |
| JOP20190025A1 (en) | 2019-02-19 |
| JP2022173308A (en) | 2022-11-18 |
| US20230074781A1 (en) | 2023-03-09 |
| EP3507384A1 (en) | 2019-07-10 |
| CN109952383B (en) | 2024-01-05 |
| JP7197915B2 (en) | 2022-12-28 |
| JP2019528705A (en) | 2019-10-17 |
| MX2019002377A (en) | 2019-09-05 |
| JP2020188816A (en) | 2020-11-26 |
| SG11201901762WA (en) | 2019-03-28 |
| KR20190046935A (en) | 2019-05-07 |
| TW202313973A (en) | 2023-04-01 |
| PH12019500422A1 (en) | 2019-05-27 |
| TWI771317B (en) | 2022-07-21 |
| TW201812125A (en) | 2018-04-01 |
| RU2019109011A3 (en) | 2021-01-22 |
| US20190233902A1 (en) | 2019-08-01 |
| WO2018045240A1 (en) | 2018-03-08 |
| US11421280B2 (en) | 2022-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286316A (en) | Novel micro-dystrophins and related methods of use | |
| HK1249058A1 (en) | Compounds and methods for the enhanced degradation of targeted proteins | |
| HK1232147A1 (en) | Cenicriviroc for the treatment of fibrosis | |
| HK1249758A1 (en) | Antimicrobial compounds and methods of making and using the same | |
| SG10201912134TA (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| ZA201905677B (en) | Glycan-interacting compounds and methods of use | |
| HK1253049A1 (en) | Glycan-interacting compounds and methods of use | |
| HK1256795A1 (en) | Bipyrazolyl derivatives useful for the treatment of autoimmune diseases | |
| GB2544180B (en) | Cover means and method of use thereof | |
| SG11201702554QA (en) | Compositions and methods for the treatment of multiple sclerosis | |
| HK1246689A1 (en) | Fixed dose combination of bromonidine and timolol | |
| EP3368048A4 (en) | Methods and compositions for the treatment of amyloidosis | |
| HK1247558A1 (en) | Cenicriviroc for the treatment of fibrosis | |
| HK1255695A1 (en) | Composition and methods for the treatment of blepharoptosis | |
| PL3113774T3 (en) | Compositions of grapiprant and methods for using the same | |
| IL255819A (en) | Improved processes for the preparation of sofosbuvir and intermediates thereof | |
| IL251588A0 (en) | Methods and compositions for increasing the potency of antifungal agents | |
| IL269681A (en) | New methods for the treatment of multiple sclerosis | |
| IL248995A0 (en) | Methods for identifying compounds that alter the activity of irhom polypeptides and use thereof | |
| ZA201608823B (en) | Processes for the preparation of azd5363 and novel intermediate used therein | |
| SG11201706369PA (en) | Compositions and methods for the treatment of mucositis | |
| EP3212195A4 (en) | Compositions and methods for treating hiv-associated cognitive dysfunction | |
| SG11201704282UA (en) | Compositions and methods for the treatment of multiple sclerosis | |
| TWM533036U (en) | Improved structure of container | |
| TWM533591U (en) | Sideway-lifting door structure of van |